Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.63 |
| ▸ | MAOA | P21397 | 8/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737854 | 0.95 | MAOB (0.59) | MAOBMAOACES2 | |
| SCHEMBL6739190 | 0.95 | MAOB (0.59) | MAOBMAOACES2 | |
| SCHEMBL29000529 | 0.86 | MAOB (0.51) | MAOBMAOAACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL29756418 | 0.85 | MAOB (0.50) | MAOBMAOAACHEALDH1A1 | |
| SCHEMBL980916 | 0.80 | MAOB (0.45) | MAOBACHEALDH1A1 | |
| SCHEMBL17763438 | 0.78 | MAOB (0.61) | MAOBMAOAACHECES2 | |
| SCHEMBL6741552 | 0.78 | MAOB (0.57) | MAOBMAOAACHECES2 | |
| SCHEMBL6741758 | 0.78 | MAOB (0.57) | MAOBMAOAACHECES2 | |
| SCHEMBL6738033 | 0.78 | MAOB (0.57) | MAOBMAOAACHECES2 | |
| SCHEMBL29693411 | 0.78 | MAOB (0.68) | MAOBMAOAACHECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773330-B | Butylphthalide-oxa/thiadiazole compound and preparation method and application thereof | 贵州医科大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-114773330-A | Butylphthalide-oxa/thiadiazole compound and preparation method and application thereof | 贵州医科大学 | 2022-07-22 | — | — | CN | disclosed |
| US-6689808-B2 | TREATING OR PREVENTING EPILEPSY OR NEURODEGENERATIVE DISEASES | LES LABORATOIRES SERVIER (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20030220393-A1 | Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-11-27 | — | — | US | disclosed |
| EP-1320528-A2 | SUBSTITUTED PHTHALIDES AS ANTI-CONVULSIVE DRUGS | THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002000638-A2 | SUBSTITUTED PHTHALIDES AS ANTI-CONVULSIVE DRUGS | INSTITUTE OF MATERIA MEDICA (CN) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220393-A1 | Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them | NR5A2, NR2E3, NR4A1 | MAOB 1112/4885MAOA 572/4885ACHE 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.